Italian Journal of Dermatology and Venereology 2021 February;156(1):36-41

DOI: 10.23736/S2784-8671.18.06032-7

lingua: Inglese

Use of fumaric acid derivatives in Italian reference centers for psoriasis

Giovanni DAMIANI ^{1, 2, 3} ✉, Simone CAZZANIGA ^{3, 4}, Luigi NALDI ^{3, 5}, PsoReal Study Group

¹ Young Dermatologists Italian Network (YDIN), Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy; ² Unit of Clinical Dermatology, Department of Biomedical, Surgical and Dental Sciences, IRCCS Galeazzi Orthopedic Institute, University of Milan, Milan, Italy; ³ Centro Studi GISED, Bergamo, Italy; ⁴ Department of Dermatology, Inselspital University Hospital, Bern, Switzerland; ⁵ Department of Dermatology, San Bortolo Hospital, AULSS8, Vicenza, Italy

HTML PDF

BACKGROUND: Several therapies are available for psoriasis, including in some countries oral fumaric acid derivatives (FADs). Even if FADs are not available in the Italian market, they can be prescribed and reimbursed by the National Health Service, on request from the treating physician, when considered as a valuable option in selected patient.
METHODS: We performed a retrospective analysis of the PsoReal registry data, restricted to adult psoriatic patients enrolled between 2009 and 2017. Demographic and clinical data were collected together with information on systemic therapies prescribed for psoriasis, drug shifts and adverse effects. We focused our analysis on FADs compared with other systemic drugs.
RESULTS: From the registry data, a total of 17,064 patients were extracted, and 11,592 patients (67.9%), fulfilled inclusion criteria. The majority of them had chronic plaque psoriasis, the mean disease duration was 17.1±12.6 years, and the mean PASI was 17.8±10.9, with 51.5% presenting a moderate Ps (PASI between 10 and 20). A total of 36 patients (0.3%) were treated by FADs. The average treatment duration of conventional (9.0±10.0 months) and biological agents (13.7±11.6 months) was lower compared to the duration of FADs (28.1±20.1, P value<0.001). FADs were used at an average dosage of 361.0±146.3 mg/day and FADs treated patients displayed an overall lower healthcare cost compared with other drugs.
CONCLUSIONS: The current study confirms previous European data about efficacy and safety of FADs and suggests a decrease of healthcare costs for FADs treated patients as compared to other treatments.

KEY WORDS: Psoriasis; Fumaric acid; Safety; Adverse effects; Hospitalization

inizio pagina

Publication History

Issue published online: April 15, 2021
Article first published online: January 9, 2019
Manuscript accepted: May 10, 2018
Manuscript received: April 6, 2018

Per citare questo articolo

Damiani G, Cazzaniga S, Naldi L; PsoReal Study Group. Use of fumaric acid derivatives in Italian reference centers for psoriasis. Ital J Dermatol Venereol 2021;156:36-41. Ital J Dermatol Venereol 2021;156:36-41 DOI: 10.23736/S2784-8671.18.06032-7

PsoReal Study Group

Gianfranco ALTOMARE (Department of Dermatology, IRCCS Galeazzi Orthopedic Clinic Institute, Milan, Italy); Giordana ANNALI (Clinic of Dermatology, Maggiore della Carità University Hospital, Novara, Italy); Annarita ANTELMI (Department of Dermatology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy); Luisa ARANCIO (Unit of Dermatology, Center for Psoriasis, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy); Piergiacomo CALZAVARA-PINTON (Clinic of Dermatology, AO Spedali Civili di Brescia, Brescia, Italy); Angelo CARABELLI (Department of Dermatology, S. Antonio Abate Hospital, Gallarate, Varese, Italy); Carlo CARRERA (Unit of Dermatology, Center for Psoriasis, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy); Angelo CATTANEO (Unit of Dermatology, Center for Psoriasis, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy); Enrico COLOMBO (Clinic of Dermatology, Maggiore della Carità University Hospital, Novara, Italy); Massimo DALY (Unit of Dermatology, Hospital of Ivrea, Ivrea, Italy); Paolo DAPAVO (Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy); Claudia DE FILIPPI (Department of Dermatology, AO Lodi, Presidio di Sant’Angelo Lodigiano, Sant’Angelo Lodigiano, Lodi, Italy); Marco DI MERCURIO (Unit of Dermatology, ASST Papa Giovanni XXIII, Bergamo, Italy); Fabrizio FANTINI (Unit of Dermatology, A. Manzoni Hospital, Lecco, Italy); Maria T. FIERRO (Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy); Silvia FOSSATI (Department of Dermatology, S. Antonio Abate Hospital, Gallarate, Varese, Italy); Chiara FRANCHI (Department of Dermatology, IRCCS Galeazzi Orthopedic Clinic Institute, Milan, Italy); Massimo GATTONI (Department of Dermatology, S. Andrea Hospital, Vercelli, Italy); Carlo GELMETTI (Unit of Dermatology, Center for Psoriasis, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy); Giuseppe LEMBO (Unit of Dermatology, Sant’Anna Hospital, Como, Italy); Piergiorgio MALAGOLI (Division of Dermatology, IRCSS San Donato Polyclinic Hospital, San Donato Milanese, Milan, Italy); Roberto MANZONI (Unit of Dermatology, Degli Infermi Hospital, Biella, Italy); Alberico MOTOLESE (Department of Dermatology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy); Michela ORTONCELLI (Department of Dermatology, Cardinal Massaia Hospital, Asti, Italy); Rossana PEILA (Unit of Dermatology, Hospital of Ivrea, Ivrea, Italy); Paolo PELLA (Unit of Dermatology, Degli Infermi Hospital, Biella, Italy); Giovanni RONCAROLO (Department of Dermatology, Cardinal Massaia Hospital, Asti, Italy); Davide STRIPPOLI (Unit of Dermatology, A. Manzoni Hospital, Lecco, Italy); Rossana TIBERIO (Clinic of Dermatology, Maggiore della Carità University Hospital, Novara, Italy); Dario TOMASINI (Department of Dermatology, Hospital of Busto Arsizio, Busto Arsizio, Varese, Italy); Marina VENTURINI (Clinic of Dermatology, AO Spedali Civili di Brescia, Brescia, Italy); Andrea ZANCA (Department of Dermatology, AO Carlo Poma, Mantova, Italy)

Corresponding author e-mail

dr.giovanni.damiani@gmail.com

I TUOI DATI

I TUOI ORDINI

CESTINO ACQUISTI

COME ORDINARE

I TUOI ABBONAMENTI

I TUOI ARTICOLI

I TUOI EBOOK

COUPON